Search
Atopobium vaginae
Pathology:
- etiologic agent of bacterial vaginosis [1]
- may be associated with 80% of cases [1], especially with therapeutic failures
Laboratory:
- Atopobium vaginae DNA in vaginal fluid
Management:
- variably resistant to metronidazole
- resistant to nalidixic acid, colistin
- nifuratel is not approved for use in the United States
- clindamycin effective but also affects lactobacilli, altering the vaginal environment [1]
- susceptible to azithromycin, penicillin, ciprofloxacin [3]
General
Coriobacteriia
Properties
KINGDOM: monera
DIVISION: SCHIZOMYCETES
References
- Polatti F
Bacterial Vaginosis, Atopobium vaginae and Nifuratel.
Curr Clin Pharmacol. 2012 Feb; 7(1): 36-30
PMID: 22082330 Free PMC Article
- Ferris MJ
Association of Atopobium vaginae, a recently described
metronidazole resistant anaerobe, with bacterial vaginosis.
BMC Infect Dis. 2004 Feb 13;4:5.
PMID: 15018635 Free PMC Article
http://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-4-5
- De Backer E, Verhelst R, Verstraelen H et al
Antibiotic susceptibility of Atopobium vaginae.
BMC Infect Dis. 2006 Mar 16;6:51
PMID: 16542416 Free PMC Article
http://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-6-51